MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.420
+0.050
+3.65%
After Hours: 1.420 0 0.00% 19:26 08/07 EDT
OPEN
1.470
PREV CLOSE
1.370
HIGH
1.480
LOW
1.380
VOLUME
1.91M
TURNOVER
--
52 WEEK HIGH
3.590
52 WEEK LOW
0.6200
MARKET CAP
71.83M
P/E (TTM)
-1.4910
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRIS stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.

EPS

CRIS News

More
Curis EPS beats by $0.03, misses on revenue
Curis (NASDAQ:CRIS): Q2 GAAP EPS of -$0.17 beats by $0.03. Revenue of $2.36M (+12.9% Y/Y) misses by $0.34M. Shares +1.5%. Press Release
seekingalpha · 2d ago
Curis Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $2.36M Miss $2.55M Estimate
Curis (NASDAQ:CRIS) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 22.73 percent increase over losses of $(0.22) per share from the same
Benzinga · 3d ago
Curis Reports Second Quarter 2020 Financial Results
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.
PR Newswire · 3d ago
3 “Strong Buy” Penny Stocks That Could Go Boom
The stock market has been holding up remarkably well, but why? Against the backdrop of weak second quarter earnings results, investors are piling in on the hope that a COVID-19 vaccine is coming, there will be additional stimulus and corporate profits will bou
TipRanks · 3d ago
Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call on August 4, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2020 financial results on Tuesday, August 4, 2020, after the
PR Newswire · 07/28 12:00
Curis Doses First Patient In Phase 1 Study of CA-4948 In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes
Benzinga · 07/07 12:14
Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4
PR Newswire · 07/07 12:00
Curis Shares Move Higher After Jones Trading Initiates Coverage With Buy Rating, Sets $5 Price Target
-Reuters
Reuters · 06/23 12:23

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About CRIS

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
More

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.